Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Investor Presentation (July 2023)
19 slides from Vivoryon Therapeutics's investor presentation, July 2023
Slide 1: Upstream intervention to address multiple hallmarks of AD
Upstream intervention to address multiple hallmarks of AD Tackling AD at the roots |Vivoryon Therapeutics N.V. – July 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Investment Highlights
Investment Highlights Late-Stage Lead Program Varoglutamstat Approach ◆ DIFFERENTIATED UPSTREAM APPROACH TO ALZHEIMER’S DISEASE treatment targeting ◆ PURPOSE-BUILT PIPELINE of small major hallmarks of disease with proven early molecules addressing medical need in signs of disease-modifying activity:
Slide 4: Key Success Factors for Drug Development in Alzheimer's Disease
Key Success Factors for Drug Development in Alzheimer’s Disease THE “RIGHTS”OF AD DRUG DEVELOPMENT1 Right Target Right Drug Right Biomarkers Right Participants Right Trial Targets appropriate Has appropriate PK/PD Guide participant selection, Are in appropriate phase of Is prudently designed and bio
Slide 5: Overcoming Challenges in Alzheimer's Disease – Our Solution
Overcoming Challenges in Alzheimer’s Disease – Our Solution ONGOING CHALLENGES IN AD VIVORYON’S APPROACH Discovered QPCT-mediated formation of a ~30 million people worldwide and expected to double by 2050, with neurotoxic Abeta variant, N3pE-Abeta (pGlu-Abeta), ~12.7 million in the US alone as drive
Slide 6: Lead Product Candidate: Varoglutamstat Prevents N3pE-formation in AD
Lead Product Candidate: Varoglutamstat Prevents N3pE-formation in AD ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS Increased activity of glutaminyl cyclase (QPCT) is Abeta CCL2 associated with AD pathology in humans1 upregulated in AD QPCT catalyzes formation of neuroto
Slide 7: Therapeutic Potential of QPCT/L Inhibition in Human AD
Therapeutic Potential of QPCT/L Inhibition in Human AD Successfully Translating In Vivo Evidence into Proof of Concept in AD Patients Abeta Pathology QPCT is essential for N3pE amyloid formation in vivo1 Dose-dependent reduction of QPCT 5XFAD mice, QPCT ko and tg QPCT/ N3pE activity in CSF & serum (
Slide 8: Varoglutamstat Clinical Development Strategy
Varoglutamstat Clinical Development Strategy Clear Path To Potential Regulatory Approval Based on Well-Informed, Extensive Phase 1 and Phase 2 Trials Pivotal study or Phase 2b VIVIAD Assessment of safety, tolerability and accelerated approval efficacy in 250 patients with MCI or FDA Fast Track desig
Slide 9: Phase 2b Study
Phase 2b Study Ongoing Assessment of Safety, Tolerability and Efficacy of Varoglutamstat in Patients with MCI and Mild AD1,2 Site visits 4 12 16 24 INTERIM SAFETY 36 48 60 72 84-96 FINAL DATA Mid-22 1Q24 w 13-24 FIRST 90 PATIENTS 1:1:1 w 25–48/96 Placebo / 300 mg / 600 mg DSMB DECISION ALL PATIENTS
Slide 10: VIVIAD Key Safety Data
VIVIAD Key Safety Data ◆ DSMB/June 2022: Safety assessment after 90th patient had reached week 24; led to selection of 600 mg, the highest well-tolerated dose, as dose for the remainder of the study ◆ No assessment of efficacy ◆ Recruitment completed with a global screening failure rate of less than
Slide 11: VIVIAD Key Safety Data Suggest Favorable Profile
VIVIAD Key Safety Data Suggest Favorable Profile TREATMENT EMERGENT ADVERSE TEAEs BY SOC N (%) EVENTS OBSERVED = OR > 5 (AS OF OCT 07, 2022) Covid 19 infection 40 (18) Diarrhea 14 (6) Headache 13 (6) Nausea 13 (6) Depression 13 (6) Fatigue 12 (5) Constipation 10 (4) Rash 9 (4) Night sweats 7 (3) Diz
Slide 12: VIVIAD: Safety Profile of Varoglutamstat Strongly Improved vs. 1st In Patient Study
VIVIAD: Safety Profile of Varoglutamstat Strongly Improved vs. 1st In Patient Study SAFETY COMPARISON VIVIAD VERSUS SAPHIR VIVIAD SAPHIR (DATA CUT-OFF JAN 5, 2023) active 300 or 600 mg 800 mg Number of subjects in study 259 120 Number of patients on drug ~154 60 Number of SAE 15 (9.7%) 13 (22%) (in
Slide 13: VIVIAD vs. SAPHIR - Informed Adjustments
VIVIAD vs. SAPHIR - Informed Adjustments Slower Titration and Lower Final Dose while Maintaining the Level of Target Inhibition Weeks 1 2 3&4 5 to 8 9 to 12 After 12 Dose and titration varoglutamstat mg SAPHIR 400 BID 800 BID 800 BID 800 BID 800 BID STOP VIVIAD 50 OD 50 OD 50 BID 150 BID 300 BID 600
Slide 14: Phase 2 Study with Option to Expand to Phase 3
Phase 2 Study with Option to Expand to Phase 3 START Site visits 4 8 12 16 24 36 48 60 72 2H21 w 1-24 PHASE 2 PHASE 2 ADAPTIVE DOSE FINDING ONGOING w 25 – 72 TREATMENT 180 patients 180 patients ENDPOINTS Placebo / 600 mg / 300 mg / 150 mg Placebo / selected dose 1:1 Primary efficacy: (all BID) (all
Slide 15: Multiple Avenues to Value Generation
Multiple Avenues to Value Generation Diverse Pipeline of Oral Small Molecule Inhibitors to Address Exceptionally High Medical Need ALZHEIMER’S DISEASE INFLAMMATION/NASH Small molecule oral QPCT/L inhibitors with good Small molecule QPCTL inhibitors to modulate the blood-brain barrier penetration CCL
Slide 16: Diverse Pipeline Addressing Severe Diseases
Diverse Pipeline Addressing Severe Diseases Program Approach Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Status Varoglutamstat SMI (PQ912) VIVIAD - Ph2b in EU Fully recruited; Final readout Q1/2024 QPCT/L Varoglutamstat SMI Ph 2a ongoing; expanded treatment (PQ912) VIVA-MIND - Ph2a/b in
Slide 17: Experienced Leadership
Experienced Leadership Seasoned Biopharma Experts Covering All Relevant Aspects of Drug Development EXECUTIVE DIRECTORS NON-EXECUTIVE DIRECTORS Ulrich Dauer, PhD Erich Platzer, MD, PhD Chief Executive Officer, Executive Director Chairman Professor Morten Asser Karsdal, MSc, PhD, mMBA Michael Schaeff
Slide 18: Positioned for Continued Value Generation
Positioned for Continued Value Generation Varoglutamstat: Differentiated Phase 2 Catalysts and Future Opportunities Asset with Unique Potential in AD ◆ UPCOMING CATALYSTS: ◆ STATISTICALLY SIGNIFICANT changes in working memory ◆ VIVIAD European Phase 2b: Final readout Q1/2024 ◆ CONVENIENT ADMINISTRAT
Slide 19: Vivoryon Therapeutics N.V. contact details
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany Munich Franz-Josef-Delonge-Str. 5 81249 München Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Investor Presentation (July 2023) on 6ix